Application of Ramucirumab Exposure-Response Modeling to Support Dose Selection for Post Marketing Studies in Patients with Gastric Cancer

被引：0

作者：

O'Brien, Lisa ^{[1
]}

Gao, Ling ^{[2
]}

Heathman, Michael ^{[1
]}

机构：

[1] Eli Lilly & Co, Indianapolis, IN 46285 USA

[2] Eli Lilly & Co, Bridgewater, NJ USA

来源：

JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS | 2016年 / 43卷

关键词：

D O I：

暂无

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

M-36

引用

页码：S28 / S28

页数：1

共 50 条

[31] Optimization of secukinumab dose regimens in patients with moderate-to-severe plaque psoriasis via exposure-response modeling
Liu, Yixiao
Xu, Ling
Wang, Xinrui
Wu, Lijuan
Cai, Ruifen
Li, Lujin
Zheng, Qingshan
EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2023, 16 (10) : 999 - 1008
[32] Phase 3 dose selection for selinexor in TP53wt endometrial cancer based on exposure-response analysis
Makker, Vicky
Richardson, Debra L.
Chon, Hye Sook
Miller, David Scott
Mau-Sorensen, Morten
Cibula, David
Zagouri, Flora
Fidalgo, Alejandro Perez
Slomovitz, Brian M.
Coleman, Robert L.
Kalyanapu, Pratheek
Fan, Rong
Gudi, Girish
Vergote, Ignace
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[33] Population pharmacokinetic modeling of asciminib in support of exposure-response and ethnic sensitivity analyses in patients with chronic myeloid leukemia
Darstein, Christelle
Yoon, Deokyong
Yang, Yiqun
Kapoor, Shruti
Dasgupta, Kohinoor
Wu, Shengyuan
Kawakita, Yasunori
Hoch, Matthias
Grosch, Kai
Sy, Sherwin K. B.
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2025, 95 (01)
[34] Exposure-Response relationship of second-line ramucirumab in East Asian patients with advanced gastric cancer from RAINBOW, a global, randomized, double-blind, phase 3 study
Kim, T. Y.
Yen, C. -J.
Al-Batran, S. -E.
Gao, L.
Ferry, D.
Hsu, Y.
Cheng, R.
Orlando, M.
Ohtsu, A.
ANNALS OF ONCOLOGY, 2016, 27 : 116 - 117
[35] Integrated exposure-response analysis of efficacy and safety of lurbinectedin to support the dose regimen in small-cell lung cancer
Fernandez-Teruel, Carlos
Fudio, Salvador
Lubomirov, Rubin
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2022, 89 (05) : 585 - 594
[36] Exposure-response (E-R) relationship of ramucirumab (RAM) from two global, randomized, double-blind, phase 3 studies of patients (Pts) with advanced second-line gastric cancer.
Tabernero, Josep
Ohtsu, Atsushi
Muro, Kei
Van Cutsem, Eric
Oh, Sang Cheul
Bodoky, Gyorgy
Shimada, Yasuhiro
Hironaka, Shuichi
Ajani, Jaffer A.
Tomasek, Jiri
Safran, Howard
Chandrawansa, Kumari
Hsu, Yanzhi
Heathman, Michael
Khan, Azhar Z.
Ni, Lan
Melemed, Allen S.
Gao, Ling
Ferry, David
Fuchs, Charles S.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
[37] Population pharmacokinetics and exposure-response relationship of amatuximab, an anti-mesothelin monoclonal antibody, in patients with malignant pleural mesothelioma and its application in dose selection
Gupta, Anubha
Hussein, Ziad
Hassan, Raffit
Wustner, Jason
Maltzman, Julia D.
Wallin, Bruce A.
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 77 (04) : 733 - 743
[38] Post-Marketing Safety Study of Ramucirumab Plus FOLFIRI: Analysis of Age and Initial Dose of Irinotecan in Patients with Metastatic Colorectal Cancer
Toshiki Masuishi
Soshi Nagaoka
Long Jin
Kenichi Yoshizawa
Drugs - Real World Outcomes, 2023, 10 : 405 - 413
[39] Post-Marketing Safety Study of Ramucirumab Plus FOLFIRI: Analysis of Age and Initial Dose of Irinotecan in Patients with Metastatic Colorectal Cancer
Masuishi, Toshiki
Nagaoka, Soshi
Jin, Long
Yoshizawa, Kenichi
DRUGS-REAL WORLD OUTCOMES, 2023, 10 (03) : 405 - 413
[40] Population Pharmacokinetics and Exposure-Response Analyses from Phase I-III Studies Support Copanlisib Dose Selection in Relapsed Indolent Non-Hodgkin Lymphoma
Moss, Jonathan
Garmann, Dirk
Austin, Rupert
Hiemeyer, Florian
Matasar, Matthew J.
Zinzani, Pier Luigi
Beckert, Vita
Soler, Lidia Mongay
Childs, Barrett H.
Morcos, Peter N.
BLOOD, 2022, 140 : 3629 - 3631

← 1 2 3 4 5 →